Jocelyn Aspa

Jocelyn always knew she wanted to be a journalist, although it took her a little time getting there. Before following her dream, Jocelyn spent several years working as a legal assistant before making the leap to go back to school. Jocelyn completed the two-year journalism diploma program at Langara College and interned at The Georgia Straight before joining Investing News Network in May 2016 as a staff writer. Now, Jocelyn is the Managing Editor the Life Science and Technology sites at INN and is driven on curating quality content for its readers. After writing previously writing on resources and technology, Jocelyn now covers the Life Science sector. When she's not writing, Jocelyn can usually be found watching sports, spending too much time finding something to watch on Netflix, and probably taking too many pictures of her cat and dog.


Paladin Labs Announces Approval of Envarsus PA™ in Canada

Paladin Labs and Endo Ventures, subsidiaries of Endo International (NASDAQ:ENDP) have announced that Health Canada’s approval of Envarsus PA is...

February 22nd, 2019

Trillium Announces Pricing of US$15 Million Public Offering of Common Share Units

Trillium Therapeutics (NASDAQ:TSX:TRIL) has announced it has priced its underwitten public offering of 6.55 million common shares of the company...

February 22nd, 2019

The Rise of CRISPR Technology

CRISPR technology is a rapidly growing component of the genetics industry. Here's what investors need to know about its future...

February 21st, 2019

Reliq Health Technologies Announces Medical Advisory Board

Reliq Health Technologies (TSXV:RHT,OTCQB:RQHTF) has announced it has formed a new medical advisory board and the appointment of the five...

February 20th, 2019

SQI Diagnostics Announces Private Placement with Insider Participation

SQI Diagnostics (TSXV:SQD;OTCQB:SQIDF) has announced it will complete a non-brokered private placement of up to 31.25 million units of the...

February 20th, 2019

Cytokinetics Announces Initiation of Phase 1 Clinical Study of AMG 594, a Cardiac Troponin Activator

Cytokinetics (NASDAQ:CYTK) has announced the first subject has been dosed in a Phase 1 randomized, double-blind, placebo-controlled and multiple ascending...

February 20th, 2019

Ovid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common and Preferred Stock

Ovid Therapeutics (NASDAQ:OVID) has announced the pricing of underwritten public offerings of 12.5 million shares of its common stock and...

February 20th, 2019